We love smart stuff. Smartwatches track our daily activity, smart fabrics monitor vital signs, smart shoes navigate our journeys and smart drugs boost cognitive functioning.
Some folks move through their healthcare buying cycle relatively quickly and others may take a year, but everyone generally goes through the phases of discovering a need, shopping around, narrowing the field and making a decision.
The health insurer will offer Fit4D's diabetes coaching program to its members after testing the program during a pilot last year.
Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs
Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.
Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.
HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.
United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.
United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.
Patients will now be able to compare plans and identify ones that have disease-specific programs.
The deal will cap the monthly price some patients may pay for medications such as Atripla.
Cigna said found paying for medications and hospitalizations were top healthcare concerns.
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.
Health insurer WellPoint found patients chose lower-priced MRIs when shown how much locations charged for the very same procedure, but the motivation is murky.
The cost of fixing healthcare.gov is hovering at around $1 billion, up from the $677-million figure quoted in December
Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.
The Centers for Medicare and Medicaid Services launched a new site Monday to help patients understand how to use their health coverage.
An early look at healthcare reforms impact indicates that allowing children to stay on a parent's healthcare plan until they turned 26 did not translate into higher use of medical care, but did lower out-of-pocket healthcare costs for the 19-25 age group.
The company signed a deal with AstraZeneca in which high-risk heart disease patients can bypass step therapy and go straight to the branded cholesterol fighter.
Companies including WellPoint and Highmark are deploying financial incentives for doctors to stick with recommended cancer treatments.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
The March 31 deadline for health insurance is not the be-all-and-end-all, while a survey found that 50% of the uninsured intend to stay that way.
The JD Powers survey shows health insurance communication opportunities.
Hospitals are contemplating financial incentives—as in fines or less support—for patients who could have signed up for health insurance but opted not to.
Official numbers are pending, but Reuters notes enrollment appears to be just 3% of the government's goal.
A roundup of some exchange-related news circling the web.
Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
A JAMA article says prostate cancer patients are getting treatments they don't need; Roche and AstraZeneca will share safety data; WellPoint gives cost sharing a new spin; Bayer seeks to boost its oncology pipeline; Takeda announces organizational changes; and the FDA puts Allergan's Restasis on track for generic competition.